Advancing Peritoneal Dialysis (PD)
Millions of patients worldwide depend on dialysis to survive.
Our novel fluid, PDprotec®, is designed
to improve the outcomes of this treatment and
reduce the burden of kidney failure for patients and health care providers.
Zytoprotec assumes that the number of dialysis patients will continue to increase significantly for many years to come. An estimated 90% of dialysates are sugar-based.
According to Zytoprotec estimates, the global market for dialysis fluids will have a volume of more than 3 EUR billion in 2021 (gross annual sales).
PDprotec® – key advantages
Improved clinical outcome
Prolonged time for which patients can benefit from PD
Increase market share of PD in dialysis overall
The Zytoprotec success story
Beginning of
Phase III
Study
> read more
- Product prepared to enter pivotal Phase III trial
- Outstanding safety and efficacy demonstrated for PDprotec® in Phase I/II and Phase II studies
- Orphan Drug designation granted by FDA
- Follow-on PD fluid ICOprotec® ready for clinical development
Award-winning science
and world-class
clinical research
Science and Technology
The development of PDprotec® has been advanced by Zytoprotec’s own scientists and clinical experts and by the expertise and support provided by global leaders in the field of PD represented in our Scientific Advisory Board.
Scientific Advisory Board
A clear step forward in next generation PD solutions."*
Prof. Dr. Nicholas Topley
They say a bit of stress is good for you – Zytoprotec research shows nicely how you can incorporate this principle into clinical practice of PD."
Prof. Dr. Janusz Witowski
Targeting peritoneal membrane barrier and transport function by PDprotec® improves PD efficacy and biocompatibility and should improve PD substantially and ultimately patient long-term outcome."*
Prof. Dr. Claus Peter Schmitt, Heidelberg
A big step toward the reservation of peritonea membrane in PD patients. An attractive approach to preserve the peritoneal membrane, complementary to the efforts to improve fluid biocompatibility, is the use of additives protecting the mesothelium. In this context, Zytoprotec, through the wise combination of basic and clinical research, has developed novel PD fluids that mitigate peritoneal damage and, as a consequence, reduce systemic side-effects of dialysis treatment."*
Prof. Dr. Manuel Lopez Cabrera
The phase2 data suggest that PDprotec will restore mesothelial integrity and inflammatory responses, providing a potential step change for PD. A sufficiently powered phase 3 study that has impacts on clinically meaningful endpoints is now required.“*
Prof. Dr. Simon Davies, Keele, United Kingdom
*Quote was made in an e-mail correspondence between the expert and Professor Aufricht